|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.88 EUR | +1.42% |
|
+0.17% | -7.24% |
| 05-13 | Spanish stocks - Factors to watch on May 13 | RE |
| 05-09 | Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026 |
Business description: Laboratorios Farmaceuticos Rovi, S.A.
- prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- pharmaceutical products manufactured under contract (44%);
- diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%).
Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Number of employees: 1,998
Sales by Activity: Laboratorios Farmaceuticos Rovi, S.A.
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Manufacturing | 472M | 619M | 644M | 600M | 494M |
Other | - | - | - | - | 99K |
Marketing | 384M | 414M | 420M | 428M | 474M |
Inter-Segment Transactions | -207M | -216M | -235M | -264M | -225M |
Geographical breakdown of sales: Laboratorios Farmaceuticos Rovi, S.A.
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Spain | 257M | 264M | 273M | 277M | 285M |
OECD Countries | 244M | 377M | 381M | 305M | 242M |
European Union | 120M | 137M | 144M | 146M | 174M |
Other Countries | 28.79M | 40.12M | 31.63M | 35.87M | 42.25M |
Executive Committee: Laboratorios Farmaceuticos Rovi, S.A.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 26/07/2007 | |
| Director of Finance/CFO | - | 31/12/2000 | |
| Chief Tech/Sci/R&D Officer | - | 31/12/2013 | |
| Corporate Officer/Principal | - | - | |
| Investor Relations Contact | - | 30/06/2008 |
Composition of the Board of Directors: Laboratorios Farmaceuticos Rovi, S.A.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 16/07/2021 | |
| Director/Board Member | - | 26/07/2007 | |
| Director/Board Member | - | 26/07/2007 | |
| Director/Board Member | - | 08/05/2019 | |
| Director/Board Member | - | 09/05/2022 | |
| Director/Board Member | - | 13/12/2022 | |
| Director/Board Member | 59 | 19/12/2019 |
Holdings: Laboratorios Farmaceuticos Rovi, S.A.
| Name | Stocks | % | Valuation |
|---|---|---|---|
| 86,264 | 0.17% | 6 M $ |
Company details: Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceúticos Rovi SA
Calle José Isbert, 2
28223, Madrid
+34 91 021 30 00
http://www.rovi.es
Group companies: Laboratorios Farmaceuticos Rovi, S.A.
| Name | Category and Sector |
|---|---|
Pan Química Farmacéutica SA
 Pan Química Farmacéutica SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Pan Química Farmacéutica SA
Pan Química Farmacéutica SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Frosst Ibérica SA
 Frosst Ibérica SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Frosst Ibérica SA
Frosst Ibérica SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.42% | +0.17% | +3.42% | +35.15% | 3.42B | |
| +2.16% | +3.17% | +43.57% | +160.28% | 1,035B | |
| -0.07% | +4.45% | +53.50% | +48.95% | 574B | |
| -0.08% | -0.08% | +17.37% | +62.66% | 397B | |
| +0.31% | +0.77% | +21.19% | +15.95% | 324B | |
| +0.99% | -0.81% | +24.62% | +16.20% | 281B | |
| +0.52% | +3.78% | +24.85% | +34.79% | 278B | |
| -0.19% | +3.97% | -45.53% | -48.30% | 193B | |
| +4.84% | +2.45% | +21.33% | +61.85% | 191B | |
| +3.61% | -2.56% | +15.16% | +61.12% | 156B | |
| Average | +1.36% | +1.35% | +17.95% | +44.87% | 343.34B | |
| Weighted average by Cap. | +1.21% | +2.38% | +29.44% | +72.95% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ROVI Stock
- Company Laboratorios Farmaceuticos Rovi, S.A.
Select your edition
All financial news and data tailored to specific country editions
